TY - JOUR
T1 - The value of programmed death ligand 1 expression in cancer patients treated with neoadjuvant chemotherapy
AU - Al-Dughaishi, Malika
AU - Shalaby, Asem
AU - Al-Ribkhi, Khawla
AU - Boudaka, Ammar
AU - Boulassel, Mohamed Rachid
AU - Saleh, Jumana
N1 - Publisher Copyright:
© 2019, Sultan Qaboos University. All rights reserved.
PY - 2019/11
Y1 - 2019/11
N2 - Programmed death ligand 1 (PD-L1) is an inhibitory molecule expressed by cancer cells to supress T-cell activity and escape anti-tumour immunity. The role of PD-L1 in cancer has been studied extensively as it is considered an important immune checkpoint against immune over-activation through its interaction with Programmed death receptor 1 (PD-1) expressed on activated lymphocytes. PD-L1 expression was found to be enhanced by chemotherapy through different proliferation pathways. However, the predictive and prognostic value for PD-L1 expression in cancer patients treated with neoadjuvant chemotherapy (NAC) is not yet established. This review focused on the potential effects of chemotherapy on PD-L1 expression and the role of PD-L1 as a prognostic and predictive marker in NAC-treated cancer patients. In addition, the potential use of this marker in clinical practice is discussed.
AB - Programmed death ligand 1 (PD-L1) is an inhibitory molecule expressed by cancer cells to supress T-cell activity and escape anti-tumour immunity. The role of PD-L1 in cancer has been studied extensively as it is considered an important immune checkpoint against immune over-activation through its interaction with Programmed death receptor 1 (PD-1) expressed on activated lymphocytes. PD-L1 expression was found to be enhanced by chemotherapy through different proliferation pathways. However, the predictive and prognostic value for PD-L1 expression in cancer patients treated with neoadjuvant chemotherapy (NAC) is not yet established. This review focused on the potential effects of chemotherapy on PD-L1 expression and the role of PD-L1 as a prognostic and predictive marker in NAC-treated cancer patients. In addition, the potential use of this marker in clinical practice is discussed.
KW - Cancer
KW - Neoadjuvant Therapy
KW - Programmed Cell Death 1 Ligand 1
KW - Programmed Cell Death 1 Receptor
UR - http://www.scopus.com/inward/record.url?scp=85077459045&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077459045&partnerID=8YFLogxK
U2 - 10.18295/squmj.2019.19.04.002
DO - 10.18295/squmj.2019.19.04.002
M3 - Review article
C2 - 31897310
AN - SCOPUS:85077459045
SN - 2075-051X
VL - 19
SP - e277-e283
JO - Sultan Qaboos University Medical Journal
JF - Sultan Qaboos University Medical Journal
IS - 4
ER -
